AbbVie Inc.
Macrocyclic MCL-1 Inhibitors and Methods of Use

Last updated:

Abstract:

The present disclosure provides for compounds of Formula (I) ##STR00001## wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

Status:
Application
Type:

Utility

Filling date:

18 Sep 2019

Issue date:

9 Jan 2020